114 related articles for article (PubMed ID: 1632975)
21. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
[TBL] [Abstract][Full Text] [Related]
23. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
24. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
[TBL] [Abstract][Full Text] [Related]
25. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
26. IL-6 is a survival prognostic factor in renal cell carcinoma.
Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
[TBL] [Abstract][Full Text] [Related]
27. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
28. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia.
Kamihira S; Atogami S; Sohda H; Momita S; Yamada Y; Tomonaga M
Cancer; 1994 Jun; 73(11):2753-8. PubMed ID: 8194016
[TBL] [Abstract][Full Text] [Related]
29. Soluble interleukin-2 receptor in patients with glomerular diseases.
Chen HS; Wu MS; Yen TS; Chen WY
Postgrad Med J; 1995 Oct; 71(840):617-22. PubMed ID: 8545291
[TBL] [Abstract][Full Text] [Related]
30. Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma.
Azuma T; Sato Y; Ohno T; Azuma M; Kume H
PLoS One; 2018; 13(7):e0199719. PubMed ID: 30044793
[TBL] [Abstract][Full Text] [Related]
31. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.
Bien E; Balcerska A
Biomarkers; 2008 Feb; 13(1):1-26. PubMed ID: 17906988
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma.
Motokura T; Kobayashi Y; Fujita A; Nakamura Y; Taniguchi T; Uchimaru K; Asano S
Leuk Lymphoma; 1995 Jan; 16(3-4):355-62. PubMed ID: 7719243
[TBL] [Abstract][Full Text] [Related]
33. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
[TBL] [Abstract][Full Text] [Related]
34. Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.
Nakata B; Chung KH; Kato Y; Yamashita Y; Inui A; Arimoto Y; Maeda K; Onoda N; Sawada T; Sowa M
Br J Cancer; 1998 Jun; 77(11):1820-4. PubMed ID: 9667652
[TBL] [Abstract][Full Text] [Related]
35. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
[TBL] [Abstract][Full Text] [Related]
36. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Eur Urol; 2002 Apr; 41(4):458-67; discussion 467-8. PubMed ID: 12074819
[TBL] [Abstract][Full Text] [Related]
38. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
39. [The level of soluble interleukin 2 receptor in esophageal carcinoma patients before and after radiotherapy].
Liu X; An H; Jiang Y
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):97-9. PubMed ID: 7656815
[TBL] [Abstract][Full Text] [Related]
40. Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?
Buccheri G; Marino P; Preatoni A; Ferrigno D; Moroni GA
Chest; 1991 Jun; 99(6):1433-7. PubMed ID: 2036827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
